The original monovalent vaccines continue to protect against serious disease from the new variants. If SARS-CoV-2 variants evolve to resist the protection against severe disease offered by vaccination or previous infection, then variant-specific vaccines will be needed. Otherwise, this authority recommends we “stop trying to prevent all symptomatic infections in healthy, young people by boosting them with vaccines containing mRNA from strains that might disappear a few months later.”

Authors found that in 23.6% of a random sample of 2,809 admissions, there were at least one adverse event. 316 of the 978 adverse events were classified as having a significant or higher severity level, and 222 were deemed to be preventable. In 6.8% of all admissions, an adverse event that could have been avoided happened, and in 1% of those cases, the incident had a serious or higher severity rating. Seven people passed away, one of which was thought to be avoidable. The most frequent adverse events (representing 39.0% of all occurrences) were adverse medication events, which were followed by surgical or other procedural events (30.4%), patient-care events (15.0%), and infections related to medical care (11.9%).

Clinically significant anxiolytic and antidepressant benefits were seen in anxious depression patients after TMS in all samples, with average reductions in GAD-7 and PHQ-9 scores of 50% or more. The PHQ-9 scores for both the anxious and nonanxious depression groups improved equally. The worried group, however, scored higher both at the beginning of the study and after TMS, leading to significantly lower categorical rates of response and remission in depressive symptoms. The shift in anxiety and depressive symptoms substantially correlated among individuals who had anxious depression.

The US Department of Health and Human Services’ (HHS) Substance Abuse and Mental Health Services Administration (SAMHSA) issued the 2021 National Survey on Drug Use and Health (NSDUH) this week. The NDSUH offers a window into Americans’ experiences with mental health disorders, substance use, and their pursuit of treatment during the second year of the COVID epidemic through chosen estimates by race, ethnicity, and age group. Enough said—the outcomes aren’t appealing.

When there was insufficient or conflicting evidence, core authors from the Autoimmune Encephalitis Alliance Clinicians Network assessed the literature and administered an electronic survey to each member to get their personal opinions. The poll received 68 responses from respondents in 17 different nations. For patients with a general presentation, 84% of responders chose corticosteroids alone or in combination with other treatments (intravenous IG or plasmapheresis), 74% for patients who presented with faciobrachial dystonic seizures, 63% for NMDAR-IgG encephalitis, and 48.5% for classical paraneoplastic encephalitis. A summary of the diagnostic and therapeutic recommendations is provided at the end of the manuscript, which also includes a detailed presentation of the survey data.

The risk of symptomatic intracranial hemorrhage was lower among the 832 patients receiving direct oral anticoagulant treatment in this cohort study involving 33,207 patients with ischemic stroke who received intravenous thrombolysis at 64 centers in Europe, Asia, Australia, and New Zealand when compared to controls who received no anticoagulation. This outcome held true across subgroups and various selection methodologies.